Contineum Therapeutics (Contineum Therapeutics) Days Sales Outstanding : 0.00 (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Contineum Therapeutics Days Sales Outstanding?

Contineum Therapeutics's average Accounts Receivable for the three months ended in Mar. 2024 was $0.00 Mil. Contineum Therapeutics's Revenue for the three months ended in Mar. 2024 was $0.00 Mil.

The historical rank and industry rank for Contineum Therapeutics's Days Sales Outstanding or its related term are showing as below:

CTNM's Days Sales Outstanding is not ranked ^*
in the Biotechnology industry.
Industry Median: 72.66
* Ranked among companies with meaningful Days Sales Outstanding only.

Contineum Therapeutics's Days Sales Outstanding stayed the same from Dec. 2022 (0.00) to Mar. 2024 (0.00).

Contineum Therapeutics Days Sales Outstanding Historical Data

The historical data trend for Contineum Therapeutics's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Contineum Therapeutics Days Sales Outstanding Chart

Contineum Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Days Sales Outstanding

Contineum Therapeutics Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Days Sales Outstanding	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Contineum Therapeutics's Days Sales Outstanding

For the Biotechnology subindustry, Contineum Therapeutics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Contineum Therapeutics's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Contineum Therapeutics's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Contineum Therapeutics's Days Sales Outstanding falls into.

Contineum Therapeutics Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Contineum Therapeutics's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	50	*	365
=	0					/	50	*	365
=	0.00

Contineum Therapeutics's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding (Q: Mar. 2024 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2023 )	+	Accounts Receivable (A: Mar. 2024 ))	/	count )	/	Revenue (A: Mar. 2024 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365 / 4
=	0					/	0	*	365 / 4
=	N/A

Contineum Therapeutics (NAS:CTNM) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Contineum Therapeutics Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Contineum Therapeutics's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Contineum Therapeutics (Contineum Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Contineum Therapeutics Inc (NAS:CTNM) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

10578 Science Center Drive, Suite 200, San Diego, CA, USA, 92121

Website

https://www.contineum-tx.com

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Contineum Therapeutics (Contineum Therapeutics) Headlines

From GuruFocus

Contineum Therapeutics Announces Pricing of Initial Public Offering

By GlobeNewswire • 04-05-2024